Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251008631> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4251008631 endingPage "2" @default.
- W4251008631 startingPage "1" @default.
- W4251008631 abstract "Keywords: Pemphigus vulgaris;Modified Regimen;Rituximab biosimilar; IVIG Pemphigus Vulgaris (PV) has been known as fatal autoimmune bullous diseases affecting the skin and mucous membranes. Here, we report that a patient with PV responded rapidly to a modified regimen of rituximab biosimilar (CT-10, Truxima®)combined with Intravenous Immunoglobulin (IVIG). A 53-year-old man presented with extensive erosions due to blistering on the whole body following initial mucosal erosions which started at 3 years ago. Laboratory tests revealed an eosinophil count of 16.7% (normal range: 0~5%) with normal liver and renal functions. Antinuclear antibody was a nuclear membrane pattern with a titer of 1:40. Anti-dsDNA, anti-Ro/La, anti-Scl-70, and anti-phospholipid antibodies were negative. Myeloperoxidase and PR3 antineutrophil cytoplasmic autoantibody were both negative. Histological examination showed suprabasala cantholysis, while direct and indirect immunofluorescence assays demonstrated a deposition of immunoglobulin G (IgG) on anintercellular surface at 1:640 dilutions (Figure. 1a, b). Based on the blistering on the whole body and characteristic biopsy result, the patient was diagnosed as PV. Although he was initially treated with topical and highdose methylprednisolone (1000 mg/day) pulse therapy for 3 consecutive days, there was no significant improvement in skin blistering lesions. We decided to administer CT-P10 combined with IVIG. We treated the patient with CT-P10 (500, 500, and 1000mg once weekly for 3 weeks) combined with IVIG (1g/ kg at first and third week). During the treatment of CT-P10 combined with IVIG, a clinical response rapidly appeared, and levels of antibodies were decreased from 1:640 to 1:40 (Figure. 1c). Disease activity was dramatically controlled within 3 weeks. It achieved the end of the consolidation phase for PV within 5 weeks after starting CT-P10 combined with IVIG (Figure. 1dg). Then, we tapered oral prednisolone and steroid-sparing agents including mycophenolate mofetil and cyclosporine for maintenance therapy. Until now, there has been no recurrence of PV on 36 months follow up." @default.
- W4251008631 created "2022-05-12" @default.
- W4251008631 creator A5008099643 @default.
- W4251008631 creator A5032659038 @default.
- W4251008631 creator A5046014308 @default.
- W4251008631 creator A5052841252 @default.
- W4251008631 creator A5073404966 @default.
- W4251008631 creator A5089279415 @default.
- W4251008631 date "2020-11-02" @default.
- W4251008631 modified "2023-10-16" @default.
- W4251008631 title "Successful Treatment of Pemphigus Vulgaris with a Modified Regimen of Rituximab Biosimilar(CT-P10) Combined with IVIG" @default.
- W4251008631 doi "https://doi.org/10.15226/2378-1726/7/5/001126" @default.
- W4251008631 hasPublicationYear "2020" @default.
- W4251008631 type Work @default.
- W4251008631 citedByCount "0" @default.
- W4251008631 crossrefType "journal-article" @default.
- W4251008631 hasAuthorship W4251008631A5008099643 @default.
- W4251008631 hasAuthorship W4251008631A5032659038 @default.
- W4251008631 hasAuthorship W4251008631A5046014308 @default.
- W4251008631 hasAuthorship W4251008631A5052841252 @default.
- W4251008631 hasAuthorship W4251008631A5073404966 @default.
- W4251008631 hasAuthorship W4251008631A5089279415 @default.
- W4251008631 hasBestOaLocation W42510086311 @default.
- W4251008631 hasConcept C126322002 @default.
- W4251008631 hasConcept C149443304 @default.
- W4251008631 hasConcept C159654299 @default.
- W4251008631 hasConcept C16005928 @default.
- W4251008631 hasConcept C163764329 @default.
- W4251008631 hasConcept C18031839 @default.
- W4251008631 hasConcept C203014093 @default.
- W4251008631 hasConcept C2780372218 @default.
- W4251008631 hasConcept C2780653079 @default.
- W4251008631 hasConcept C2781313415 @default.
- W4251008631 hasConcept C2781413609 @default.
- W4251008631 hasConcept C71924100 @default.
- W4251008631 hasConcept C90924648 @default.
- W4251008631 hasConceptScore W4251008631C126322002 @default.
- W4251008631 hasConceptScore W4251008631C149443304 @default.
- W4251008631 hasConceptScore W4251008631C159654299 @default.
- W4251008631 hasConceptScore W4251008631C16005928 @default.
- W4251008631 hasConceptScore W4251008631C163764329 @default.
- W4251008631 hasConceptScore W4251008631C18031839 @default.
- W4251008631 hasConceptScore W4251008631C203014093 @default.
- W4251008631 hasConceptScore W4251008631C2780372218 @default.
- W4251008631 hasConceptScore W4251008631C2780653079 @default.
- W4251008631 hasConceptScore W4251008631C2781313415 @default.
- W4251008631 hasConceptScore W4251008631C2781413609 @default.
- W4251008631 hasConceptScore W4251008631C71924100 @default.
- W4251008631 hasConceptScore W4251008631C90924648 @default.
- W4251008631 hasIssue "5" @default.
- W4251008631 hasLocation W42510086311 @default.
- W4251008631 hasOpenAccess W4251008631 @default.
- W4251008631 hasPrimaryLocation W42510086311 @default.
- W4251008631 hasRelatedWork W2010282370 @default.
- W4251008631 hasRelatedWork W2047535890 @default.
- W4251008631 hasRelatedWork W2119849564 @default.
- W4251008631 hasRelatedWork W2136868555 @default.
- W4251008631 hasRelatedWork W2145322348 @default.
- W4251008631 hasRelatedWork W2267461420 @default.
- W4251008631 hasRelatedWork W2405627905 @default.
- W4251008631 hasRelatedWork W2883098082 @default.
- W4251008631 hasRelatedWork W4251008631 @default.
- W4251008631 hasRelatedWork W607571120 @default.
- W4251008631 hasVolume "7" @default.
- W4251008631 isParatext "false" @default.
- W4251008631 isRetracted "false" @default.
- W4251008631 workType "article" @default.